CA2004239A1 - Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement - Google Patents

Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement

Info

Publication number
CA2004239A1
CA2004239A1 CA2004239A CA2004239A CA2004239A1 CA 2004239 A1 CA2004239 A1 CA 2004239A1 CA 2004239 A CA2004239 A CA 2004239A CA 2004239 A CA2004239 A CA 2004239A CA 2004239 A1 CA2004239 A1 CA 2004239A1
Authority
CA
Canada
Prior art keywords
treatment
carnitine
acetyl
glaucoma
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2004239A
Other languages
English (en)
Other versions
CA2004239C (fr
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Claudio Cavazza
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claudio Cavazza, Sigma-Tau Industrie Farmaceutiche Riunite S.P.A filed Critical Claudio Cavazza
Publication of CA2004239A1 publication Critical patent/CA2004239A1/fr
Application granted granted Critical
Publication of CA2004239C publication Critical patent/CA2004239C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002004239A 1988-12-01 1989-11-30 Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement Expired - Lifetime CA2004239C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT48614A/88 1988-12-01
IT8848614A IT1224795B (it) 1988-12-01 1988-12-01 Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento

Publications (2)

Publication Number Publication Date
CA2004239A1 true CA2004239A1 (fr) 1990-06-01
CA2004239C CA2004239C (fr) 1999-11-09

Family

ID=11267644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002004239A Expired - Lifetime CA2004239C (fr) 1988-12-01 1989-11-30 Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement

Country Status (13)

Country Link
US (2) US5145871A (fr)
EP (1) EP0446268B1 (fr)
JP (1) JP2763400B2 (fr)
KR (1) KR950004885B1 (fr)
AU (1) AU628116B2 (fr)
CA (1) CA2004239C (fr)
DK (1) DK175891B1 (fr)
ES (1) ES2040106T3 (fr)
GR (1) GR1000465B (fr)
IE (1) IE62568B1 (fr)
IT (1) IT1224795B (fr)
WO (1) WO1990006111A1 (fr)
ZA (1) ZA899176B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US5629345A (en) * 1993-07-23 1997-05-13 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
EP0951909B2 (fr) 1998-03-19 2010-10-20 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition pharmaceutique contenant du L-carnitine ou de l'alkanoyl-L-carnitine, un glycosaminoglycane et/ou un élément constituif de glycosaminoglycanes
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
AU2001237939A1 (en) * 2000-02-08 2001-08-20 Gulgun Tezel Methods for treating glaucoma
PT1404642E (pt) * 2001-07-06 2010-03-29 Basf Se Processo para a preparação de derivados do ácido 7-amino sin 3,5-dihidroxi heptanoico, intermediários respectivos e métodos para a sua preparação
ATE349554T1 (de) * 2001-10-31 2007-01-15 Alcon Inc Knochen-morphogene proteine (bmp), bmp-rezeptoren und bmp-bindungsproteine und ihre verwendung bei der diagnose und behandlung des glaukoms
ITRM20020492A1 (it) * 2002-10-01 2004-04-02 Sigma Tau Ind Farmaceuti Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma.
AU2004212004B2 (en) 2003-02-13 2008-01-10 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
EP2112920B1 (fr) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
US7718697B2 (en) * 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
EP2363126A1 (fr) 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprenant une L-carnitine en tant que principe actif en combinaison avec le glucoside de l'hydroxykynurénine, pour la prévention et/ou le traitement de pathologies de l'oeil dues au rayonnement ultraviolet
WO2012069221A1 (fr) 2010-11-22 2012-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Méthode thérapeutique de traitement de la neuropathie optique de leber
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9314528B2 (en) 2011-12-07 2016-04-19 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP2783695A1 (fr) 2013-03-28 2014-10-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Supplément physioloqiue ou médicament à usage ophtalmique contenant de la L-carnitine ou des L-carnitines alcanoyles en combinaison avec eledoisin
MX2017006474A (es) 2014-11-25 2017-09-12 Allergan Inc Composiciones oftalmicas estabilizadas de omega 3.
IT201900002913A1 (it) 2019-03-01 2020-09-01 Nicola Pescosolido Composto utile per il trattamento del glaucoma
IT202100020729A1 (it) 2021-08-02 2023-02-02 Univ Degli Studi Di Napoli Federico Ii Preparazione combinata per il trattamento della malattia di Pompe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1262864A (fr) * 1982-09-17 1989-11-14 Clarence D. Cone Methode de production d'une oncolyse

Also Published As

Publication number Publication date
CA2004239C (fr) 1999-11-09
WO1990006111A1 (fr) 1990-06-14
DK175891B1 (da) 2005-05-30
GR890100797A (en) 1991-03-15
IE893840L (en) 1990-06-01
KR950004885B1 (ko) 1995-05-15
US5432199A (en) 1995-07-11
ZA899176B (en) 1990-09-26
EP0446268B1 (fr) 1993-04-14
DK95091A (da) 1991-05-21
IT8848614A0 (it) 1988-12-01
AU628116B2 (en) 1992-09-10
ES2040106T3 (es) 1993-10-01
JPH04502161A (ja) 1992-04-16
KR920702216A (ko) 1992-09-03
JP2763400B2 (ja) 1998-06-11
IT1224795B (it) 1990-10-24
IE62568B1 (en) 1995-02-08
AU4658489A (en) 1990-06-26
EP0446268A1 (fr) 1991-09-18
US5145871A (en) 1992-09-08
DK95091D0 (da) 1991-05-21
GR1000465B (el) 1992-07-30

Similar Documents

Publication Publication Date Title
CA2004239A1 (fr) Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement
EP0375628A3 (fr) Utilisation de l'acétyle-L-carnitine pour le traitement de la cataracte et compositions pharmaceutiques utilisables pour ce traitement
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
CA2239174A1 (fr) Nouveaux composes a effet analgesique
CA2274074A1 (fr) Nouveaux composes a effet analgesique
AU6060896A (en) Oral 1alpha-hydroxyprevitamin D
EP0513702A3 (fr) Dérivés de la mélatonine utiles dans le traitement des troubles du sommeil et en pré-anesthésie
CA2214097A1 (fr) Emploi de ketorolac pour le traitement d'epithelioma spinocellulaires de la cavite buccale ou de l'arriere gorge
CA2179540A1 (fr) Composition a liberation acceleree contenant de la bromocryptine
CA2233457A1 (fr) Compositions pharmaceutiques a base de dipeptide angiostatique et leur procede d'utilisation
CA2289717A1 (fr) Nouveau traitement de la constipation
AU7921887A (en) Therapeutic agents
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CA2143610A1 (fr) Utilisation de norastemizole pour le traitement de troubles allergiques
CA2202397A1 (fr) Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et procedes de traitement de troubles metaboliques et cardiovasculaires
CA2038744A1 (fr) Composition pharmaceutique contenant un medicament legerement hydrosoluble
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
CA2052901A1 (fr) Formulations a action pharmacologique accrue
CA2180178A1 (fr) Utilisation des derives 2,3-diaryl-1-benzopyrane dans la production d'un medicament employe dans le traitement et la prevention de la diminution du volume du tissu osseux et de l'osteoporose
CA2120001A1 (fr) Composition pharmaceutique a base de flavopereirine et son utilisation contre le vih
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
CA2235951A1 (fr) Nouveaux emplois du ctla-8 de mammifere et reactifs associes
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry